![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DDB2 |
Gene summary for DDB2 |
![]() |
Gene information | Species | Human | Gene symbol | DDB2 | Gene ID | 1643 |
Gene name | damage specific DNA binding protein 2 | |
Gene Alias | DDBB | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q92466 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1643 | DDB2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.33e-09 | 6.62e-01 | -0.0811 |
1643 | DDB2 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.20e-02 | 3.49e-01 | -0.1088 |
1643 | DDB2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.25e-08 | 6.56e-01 | -0.059 |
1643 | DDB2 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.25e-03 | 2.69e-01 | 0.096 |
1643 | DDB2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.11e-02 | 3.73e-01 | 0.0588 |
1643 | DDB2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.67e-02 | 3.30e-01 | 0.3005 |
1643 | DDB2 | A015-C-203 | Human | Colorectum | FAP | 2.79e-03 | -6.81e-02 | -0.1294 |
1643 | DDB2 | A015-C-104 | Human | Colorectum | FAP | 1.10e-02 | -8.53e-02 | -0.1899 |
1643 | DDB2 | LZE4T | Human | Esophagus | ESCC | 5.16e-07 | 2.00e-01 | 0.0811 |
1643 | DDB2 | LZE8T | Human | Esophagus | ESCC | 8.97e-03 | 1.66e-01 | 0.067 |
1643 | DDB2 | LZE20T | Human | Esophagus | ESCC | 2.76e-06 | 1.41e-01 | 0.0662 |
1643 | DDB2 | LZE22D1 | Human | Esophagus | HGIN | 6.66e-03 | 1.20e-01 | 0.0595 |
1643 | DDB2 | LZE24T | Human | Esophagus | ESCC | 5.52e-07 | 4.58e-01 | 0.0596 |
1643 | DDB2 | P1T-E | Human | Esophagus | ESCC | 4.46e-06 | 3.69e-01 | 0.0875 |
1643 | DDB2 | P2T-E | Human | Esophagus | ESCC | 2.18e-30 | 6.08e-01 | 0.1177 |
1643 | DDB2 | P4T-E | Human | Esophagus | ESCC | 5.57e-16 | 2.38e-01 | 0.1323 |
1643 | DDB2 | P5T-E | Human | Esophagus | ESCC | 1.02e-09 | 6.88e-02 | 0.1327 |
1643 | DDB2 | P8T-E | Human | Esophagus | ESCC | 2.15e-09 | 2.50e-01 | 0.0889 |
1643 | DDB2 | P9T-E | Human | Esophagus | ESCC | 1.02e-09 | 1.67e-01 | 0.1131 |
1643 | DDB2 | P10T-E | Human | Esophagus | ESCC | 3.66e-19 | 3.41e-01 | 0.116 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003352213 | Esophagus | ESCC | histone H2A ubiquitination | 23/8552 | 26/18723 | 6.82e-06 | 6.90e-05 | 23 |
GO:00103904 | Esophagus | ESCC | histone monoubiquitination | 25/8552 | 29/18723 | 7.24e-06 | 7.20e-05 | 25 |
GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
GO:00062891 | Esophagus | ESCC | nucleotide-excision repair | 42/8552 | 60/18723 | 1.18e-04 | 8.14e-04 | 42 |
GO:00355182 | Esophagus | ESCC | histone H2A monoubiquitination | 15/8552 | 17/18723 | 3.48e-04 | 2.03e-03 | 15 |
GO:00714821 | Esophagus | ESCC | cellular response to light stimulus | 75/8552 | 123/18723 | 4.45e-04 | 2.50e-03 | 75 |
GO:00518658 | Esophagus | ESCC | protein autoubiquitination | 47/8552 | 73/18723 | 9.72e-04 | 4.93e-03 | 47 |
GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
GO:000020910 | Oral cavity | OSCC | protein polyubiquitination | 150/7305 | 236/18723 | 1.59e-14 | 9.27e-13 | 150 |
GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
GO:007121416 | Oral cavity | OSCC | cellular response to abiotic stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:010400416 | Oral cavity | OSCC | cellular response to environmental stimulus | 186/7305 | 331/18723 | 1.38e-10 | 4.10e-09 | 186 |
GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
GO:00346444 | Oral cavity | OSCC | cellular response to UV | 63/7305 | 90/18723 | 2.42e-09 | 5.60e-08 | 63 |
GO:00165746 | Oral cavity | OSCC | histone ubiquitination | 38/7305 | 47/18723 | 5.22e-09 | 1.14e-07 | 38 |
GO:00714788 | Oral cavity | OSCC | cellular response to radiation | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
GO:00065135 | Oral cavity | OSCC | protein monoubiquitination | 47/7305 | 67/18723 | 2.32e-07 | 3.68e-06 | 47 |
GO:00103903 | Oral cavity | OSCC | histone monoubiquitination | 24/7305 | 29/18723 | 1.74e-06 | 2.26e-05 | 24 |
GO:00335224 | Oral cavity | OSCC | histone H2A ubiquitination | 21/7305 | 26/18723 | 1.66e-05 | 1.64e-04 | 21 |
GO:00094164 | Oral cavity | OSCC | response to light stimulus | 159/7305 | 320/18723 | 5.98e-05 | 4.92e-04 | 159 |
Page: 1 2 3 4 5 6 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa05213 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa05216 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa05220 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa05212 | Colorectum | AD | Pancreatic cancer | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa052131 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa052161 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa052101 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa052201 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa052121 | Colorectum | AD | Pancreatic cancer | 29/2092 | 76/8465 | 6.25e-03 | 2.68e-02 | 1.71e-02 | 29 |
hsa052162 | Colorectum | MSS | Thyroid cancer | 21/1875 | 37/8465 | 4.98e-06 | 6.00e-05 | 3.68e-05 | 21 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa052202 | Colorectum | MSS | Chronic myeloid leukemia | 29/1875 | 76/8465 | 1.10e-03 | 6.27e-03 | 3.84e-03 | 29 |
hsa05169 | Colorectum | MSS | Epstein-Barr virus infection | 63/1875 | 202/8465 | 1.63e-03 | 8.98e-03 | 5.50e-03 | 63 |
hsa052122 | Colorectum | MSS | Pancreatic cancer | 26/1875 | 76/8465 | 1.04e-02 | 3.69e-02 | 2.26e-02 | 26 |
hsa05222 | Colorectum | MSS | Small cell lung cancer | 30/1875 | 92/8465 | 1.31e-02 | 4.30e-02 | 2.64e-02 | 30 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDB2 | SNV | Missense_Mutation | c.716N>A | p.Arg239Lys | p.R239K | Q92466 | protein_coding | tolerated(0.99) | benign(0.049) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
DDB2 | deletion | Frame_Shift_Del | novel | c.1034delA | p.His345LeufsTer25 | p.H345Lfs*25 | Q92466 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
DDB2 | SNV | Missense_Mutation | c.807N>G | p.Ile269Met | p.I269M | Q92466 | protein_coding | tolerated(0.09) | possibly_damaging(0.732) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
DDB2 | SNV | Missense_Mutation | novel | c.145N>C | p.Asp49His | p.D49H | Q92466 | protein_coding | deleterious(0.01) | possibly_damaging(0.674) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
DDB2 | SNV | Missense_Mutation | rs375649516 | c.1126N>A | p.Asp376Asn | p.D376N | Q92466 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1200C>A | p.Phe400Leu | p.F400L | Q92466 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1019N>C | p.Ile340Thr | p.I340T | Q92466 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1028N>T | p.Ala343Val | p.A343V | Q92466 | protein_coding | deleterious(0.01) | benign(0.023) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DDB2 | SNV | Missense_Mutation | novel | c.1276N>T | p.Arg426Trp | p.R426W | Q92466 | protein_coding | deleterious(0) | benign(0) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
DDB2 | SNV | Missense_Mutation | novel | c.863N>T | p.Arg288Met | p.R288M | Q92466 | protein_coding | deleterious(0.04) | benign(0.251) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |